Pinnacle Clinical Research: Company Profile
Background
Overview
Pinnacle Clinical Research (PCR) is a leading network of clinical research sites specializing in complex therapeutic areas, including liver disease, metabolic disorders, memory loss, and neurodegenerative conditions. Established in 2016 and headquartered in San Antonio, Texas, PCR has expanded its operations to multiple locations across the United States. The company is dedicated to conducting high-quality, patient-focused studies that accelerate medical breakthroughs and bring innovative treatments to patients.
Mission and Vision
PCR's mission is to improve lives through innovation in clinical trials by providing exceptional patient care and advancing medical science. The company's vision is to be a premier clinical research network that partners with leading sponsors, contract research organizations (CROs), and healthcare providers to drive medical advancements.
Primary Area of Focus
PCR specializes in conducting clinical trials across a broad range of therapeutic areas, with particular expertise in liver disease, metabolic disorders, memory loss, and neurodegenerative conditions. The company is recognized for its proficiency in managing complex clinical trials and delivering reliable data.
Industry Significance
As a prominent clinical research organization, PCR plays a crucial role in advancing medical research by providing high-quality data and facilitating the development of new treatments. The company's commitment to patient-centered research and operational excellence has established it as a trusted partner for pharmaceutical companies and healthcare providers.
Key Strategic Focus
Core Objectives
- Accelerate Medical Breakthroughs: PCR aims to expedite the development of new treatments by conducting efficient and high-quality clinical trials.
- Enhance Patient Access: The company strives to provide diverse patient populations with access to cutting-edge therapies, ensuring inclusivity in clinical research.
- Operational Excellence: PCR focuses on maintaining high scientific standards and exceptional patient experiences to deliver reliable and timely results.
Specific Areas of Specialization
- Liver Disease: Expertise in non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
- Metabolic Disorders: Specialization in metabolic-associated steatohepatitis (MASH), metabolic-associated fatty liver disease (MAFLD), obesity, cholesterol management, and diabetes.
- Neurology: Focus on Alzheimer's disease and related dementias.
Key Technologies Utilized
- Advanced Diagnostic Tools: Utilization of state-of-the-art equipment, including DEXA systems for body composition analysis, ECG, ultrasound, and spirometry.
- Patient Recruitment Strategies: Robust recruitment methodologies to ensure diverse and representative patient enrollment.
Primary Markets Targeted
PCR targets pharmaceutical companies, contract research organizations (CROs), and healthcare providers seeking reliable and efficient clinical trial sites, particularly in complex therapeutic areas. The company also focuses on underserved patient populations to enhance inclusivity in clinical research.
Financials and Funding
Funding History
In November 2022, LongueVue Capital (LVC) partnered with PCR, providing growth capital to support the company's expansion and operational excellence.
Recent Funding Rounds
Specific details regarding recent funding rounds are not publicly disclosed.
Notable Investors
- LongueVue Capital (LVC): An equity investment firm that focuses on providing transformational growth capital to middle-market companies.
Intended Utilization of Capital
The capital from LVC is intended to support PCR's expansion efforts, enhance operational capabilities, and facilitate the execution of complex clinical trials across various therapeutic areas.
Pipeline Development
Key Pipeline Candidates
PCR is involved in conducting clinical trials for various pharmaceutical sponsors, focusing on complex therapeutic areas such as liver disease, metabolic disorders, and neurodegenerative conditions. Specific details about pipeline candidates are not publicly disclosed.
Stages of Clinical Trials
PCR manages clinical trials across all phases, from Phase I (First-in-Human) to Phase IV (post-market studies), ensuring comprehensive support for drug and device development.
Target Conditions
- Liver Disease: NAFLD, NASH, MASH, MAFLD.
- Metabolic Disorders: Obesity, diabetes, cholesterol management.
- Neurology: Alzheimer's disease and related dementias.
Relevant Timelines for Anticipated Milestones
Specific timelines for clinical trial milestones are not publicly disclosed.
Technological Platform and Innovation
Proprietary Technologies
PCR utilizes advanced diagnostic and monitoring equipment, including DEXA systems, ECG, ultrasound, and spirometry, to ensure accurate and reliable clinical trial data.
Significant Scientific Methods
- Patient Recruitment Strategies: Robust methodologies to ensure diverse and representative patient enrollment.
- Clinical Trial Management: Expert coordination of clinical trials across all phases, ensuring compliance and data integrity.
AI-Driven Capabilities
Specific details regarding AI-driven capabilities are not publicly disclosed.
Leadership Team
Key Executive Profiles
- Dr. Stephen Harrison: Chairman of Pinnacle Clinical Research.
- Dr. Rashmee Patil: CEO of Pinnacle Clinical Research.
- Dr. Diana Kerwin: CNS Medical Director of Pinnacle Clinical Research.
- Dr. Michelle Papka: CNS Scientific Director of Pinnacle Clinical Research.
Professional Backgrounds
- Dr. Stephen Harrison: Renowned physician with extensive experience in hepatology and clinical research.
- Dr. Rashmee Patil: Founder and CEO of South Texas Research Institute, specializing in hepatology and complex clinical trials.
- Dr. Diana Kerwin: Founder of Kerwin Medical Center, focusing on Alzheimer's disease and related dementias.
- Dr. Michelle Papka: Founder of The Cognitive and Research Center of New Jersey, specializing in Alzheimer's disease.
Key Contributions or Roles Within the Company
- Dr. Stephen Harrison: Provides strategic direction and leadership for the company.
- Dr. Rashmee Patil: Leads the company's operations and strategic initiatives.
- Dr. Diana Kerwin: Oversees clinical trials related to central nervous system disorders.
- Dr. Michelle Papka: Leads clinical trials focusing on Alzheimer's disease and related dementias.
Leadership Changes
Recent Significant Changes or Appointments
- January 2023: Dr. Rashmee Patil assumed the role of CEO following the combination with South Texas Research Institute.
- June 2024: Pinnacle expanded its network by acquiring Kerwin Medical Center, The Cognitive and Research Center of New Jersey, Bellaire Clinical Research, Palmetto Clinical Research – Low Country, and Dallas Research Institute.
Competitor Profile
Market Insights and Dynamics
The clinical research industry is characterized by rapid advancements in medical science, increasing demand for innovative treatments, and a growing emphasis on patient-centric research. Companies like Pinnacle Clinical Research play a pivotal role in bridging the gap between pharmaceutical development and patient access to new therapies.
Competitor Analysis
Pinnacle Clinical Research operates in a competitive landscape with several notable competitors, including:
- IQVIA: A global leader in healthcare data analytics and contract research services.
- Blue Matter Consulting: Provides strategic consulting services to the pharmaceutical industry.
- MCRA: Specializes in regulatory and reimbursement consulting for medical devices.
- PharmAla Biotech: Focuses on the development and commercialization of psychedelic compounds.
- CHDR: Conducts early-phase clinical trials and research.
- CATALIS: Provides clinical trial management services.
